Conventional Cancer Treatment

[Anonymous]

There are two crucial and unmet needs of cancer survivors who were treated with conventional cancer therapy:

1. Maintaining the remission: Without the elimination of cancer stem cells (CSCs)*, senescent cancer cells (SCCs)**, and reversal of immunosenescence***, long-term survival may be unlikely. Using repurposed drugs and bioavailable plant flavonoids, we can kill CSCs and prevent them from entering a dormant and more resistant state, we can kill SCCs and inhibit their tumor-promoting effects, and we can boost NK cell production in the bone marrow and regenerate thymic tissue and boost cytotoxic T-lymphocyte production.
2. Reversing the left-over damage: Chemotherapy, radiation, and the cancer itself can damage the heart, lungs, brain, nerves, kidneys, urinary bladder, liver, intestines, bone marrow, immune system, muscles, and reproductive organs. Using repurposed drugs and bioavailable plant flavonoids, it may now be possible to begin reversing tissue damage and restore quality of life.

Dr. Daniel Thomas, DO, MS

NewHopeForCancer.com

* Cancer stem cells (CSCs) are subset of cancer cells that are also known as tumor-initiating cells (TICs) and tumor-survival cells (TSCs). Many experts believe that successful eradication of CSCs could revolutionize the treatment of cancer. Not only are CSCs thought to be the main driver of the growth and spread of cancer, treatment resistance, and disease recurrence, CSCs may also be the root cause of the original tumor itself. Because of the numerous and robust survival mechanisms of CSCs, chemotherapy, radiation, and surgery are unable to target them. In fact, conventional therapy can do the exact opposite and stimulate the proliferation and virulence of CSCs. CSCs can migrate and nest in various areas of the body and remain dormant for months, years, or even decades until the right stimulus comes along and awakens them. While conventional therapy can eradicate the bulk (main) tumor cells, sooner or later, lingering CSCs can form new and often more aggressive tumors from a small number of cells (as few as 100). In other words, being “tumor-free” is not the same as being “cancer-free.” Eradicating the bulk tumor cells is not enough. CSCs must also be eradicated to achieve long-term survival. At present, there are no drugs that are FDA-approved to specifically target CSCs. To address this critical and unmet need, we are pioneering the use of repurposed drugs and plant-derived compounds that have been shown to target CSCs by directly killing them and/or preventing them from entering a dormant and more resistant state.

 

** Besides cancer stem cells, the other problematic cells are senescent cancer cells (SCCs). Not all cancer cells can be forced into apoptosis (programmed cell death) when treated with conventional or alternative therapy. Instead of dying, some cancer cells will simply stop dividing and multiplying and enter a senescent or dormant-like state. This is called senescence-associated growth arrest (SAGA), and while it sounds good, it is accompanied by something not so good called senescence-associated secretory phenotype (SASP) in which there is overactive secretion of pro-inflammatory, cancer-promoting compounds. It is good that SCCs don’t divide and multiply like regular cancer cells, however, because senescent cancer cells don’t die, they retain their dysfunctional cellular metabolism and continue to secrete pro-inflammatory, cancer-promoting compounds. If too many SCCs accumulate and the immune system doesn’t kill enough of them, this can lead to further growth and spread of cancer. Because cancer patients are usually immunosuppressed due to disease and/or treatment, we are pioneering the use of repurposed drugs and plant-derived compounds that have been shown to target senescent cells by directly killing them and/or curbing the effects of SASP.

 

*** An effective immune system can identify and destroy nascent (emerging) cancer cells in a process called immunosurveillance, which functions as our primary defense against cancer. Advancing age is associated with a decline in immune function, known as immunosenescence. Contributing factors include declining bone marrow activity and atrophy of the thymus gland, resulting in a reduction of Natural Killer (NK) cells and cytotoxic T-lymphocytes. This impairs immunosurveillance and leads to an accumulation of cancer cells, cancer stem cells, and senescent cancer cells. Recent scientific studies have shown that by using repurposed drugs and plant-derived compounds, it is possible to reverse immunosenescence by boosting NK cell production in the bone marrow and regenerating thymic tissue and boosting cytotoxic T-lymphocyte production.

 

[Author]

Posts